An in vivo development of Pantoea agglomerans mutants (isolates PA2 to PA4) with reduced ertapenem susceptibility from that of isolate PA1 was associated with an inadequate clinical response to ertapenem therapy. All four isolates harbored the bla ACT-9 AmpC ␤-lactamase gene. However, a loss-of-function mutation in the ampD gene in PA2 to PA4, but not PA1, led to derepressed ACT-9. The reduced ertapenem susceptibility caused by derepressed ACT-9 was confirmed with an ampD knockout mutant of PA1.
Ertapenem has in vitro activity against most Enterobacteriaceae (2) . However, strains that are nonsusceptible to ertapenem have arisen in recent years due to production of carbapenemases and to production of AmpC ␤-lactamases or extended-spectrum ␤-lactamases (ESBLs) with alterations of the porins (6, 7, 11) . The Clinical and Laboratory Standards Institute (CLSI) issued an update in June 2010, lowering the susceptibility breakpoint for ertapenem against Enterobacteriaceae from Յ1 to Յ0.25 g/ml (5). The revision was based on the uncertain clinical efficacy of carbapenems for treating infections caused by Enterobacteriaceae, mostly carbapenemase producers, with MICs in the new intermediate range. However, the clinical impact of bacteria with reduced susceptibility to ertapenem because of resistance mechanisms other than carbapenemase production is rarely described. Here we report on a patient with a bacteremic liver abscess where Pantoea agglomerans developed reduced susceptibility to ertapenem in vivo, which led to an inadequate response to ertapenem therapy.
A 75-year-old man visited the emergency room (ER) due to fever after radiofrequency ablation (RFA) therapy for his hepatocellular carcinoma. Oral antibiotics were given. However, febrile episodes recurred 3 days later. He visited the ER again, and a post-RFA liver abscess was diagnosed. Blood cultures obtained on the first arrival (designated isolate PA1), at the second visit (PA2), and on the following two days (PA3 and PA4) all grew P. agglomerans, identified by 16S rRNA sequence analysis (16) . Pulsed-field gel electrophoresis (PFGE) (15) indicated that they were the same clone. While PA1 was resistant to cephamycins, PA2, PA3, and PA4 exhibited additional resistance to ertapenem and extended-spectrum ␤-lactams (Table 1) . After ertapenem therapy, the patient's condition stabilized gradually, but a low-grade fever persisted. The antibiotic was shifted to imipenem-cilastatin. His fever subsided and did not relapse after initiation of the aspiration and drainage of the abscess (Fig. 1) .
No known ESBL or carbapenemase was detected in PA1 to PA4 by phenotypic (4, 8, 13) or PCR (1, 8, 12) methods. A phenotypic method was used for detection of AmpC production (17) . All isolates except the isolate PA1 were phenotypically positive for AmpC ␤-lactamase production. However, an ampC gene, bla ACT-9 (GenBank accession no. HQ693810), was identified in all isolates (amplified with primers ACT-AmpC-F [5Ј-ATGATGACWAAATCCCTWWGCTG-3Ј] and ACTAmpC-R [5Ј-TTACTACAGCGCGCTCAAAATAC-3Ј]). Attempts to transfer ␤-lactam resistance by both conjugating and transforming Escherichia coli failed.
Analysis by reverse transcription (RT)-PCR revealed that bla ACT-9 was overexpressed in isolates PA2, PA3, and PA4. The cDNAs were subsequently quantified by real-time PCR amplification with primers specific to the bla ACT-9 and ampD genes using the ABI 7000 real-time PCR system (Applied Biosystems, Foster City, CA). Expression level results were standardized relative to the transcription levels of the 16S rRNA genes for each isolate. Negative-control experiments without reverse transcription were performed to detect DNA contamination in the purified RNA. The real-time PCR results demonstrated that bla ACT-9 mRNA expression increased 158-fold in isolate PA2, 131-fold in PA3, and 129-fold in PA4 compared with that in PA1. Analyzing the region upstream of bla ACT-9 via inverse PCR revealed a partial 5Ј ampR sequence and overlapping, divergent bla ACT-9 and ampR promoter regions. The possibility of promoter modification was excluded because the sequences of the entire ampR-ampC region (amplified with primers AmpR-R [5Ј-CTGGTGGAGAAGATGA AAAAGT-3Ј] and ACT-AmpC-R [5Ј-TTACTACAGCGCGC TCAAAATAC-3Ј]) (GenBank accession no. HQ693810) were the same in all of the isolates. We further investigated the mechanism of bla ACT-9 overexpression by sequencing the ampD genes (amplified with primers AmpD-F [5Ј-ATGTTGT TAGAAAACGGATGGCT-3Ј] and AmpD-R [5Ј-TCATGTT ATCTCCTTATCTGACG-3Ј]) and identifying a single nucleotide change (T to G) at nucleotide position 492 in PA2, PA3, and PA4 (GenBank accession no. HQ685842) but not in PA1 (GenBank accession no. HQ685841). This change predicts an amino acid substitution from aspartic acid to glutamic acid in codon 164, which has been identified as the site of an inactivating point mutation (14) .
The role of the ampD gene in bla ACT-9 overexpression and ␤-lactam resistance was further explored by constructing an ampD knockout strain of PA1 (PA1⌬ampD) using the sitedirected-insertion method with an insertion of the kanamycin resistance gene, as previously described (3) . No ampD expression was detectable in PA1⌬ampD, and the bla ACT-9 gene was overexpressed in PA1⌬ampD compared to PA1. The bla ACT-9 transcription level was 230-fold higher in PA1⌬ampD than in PA1. The PA1⌬ampD mutant revealed an antibiotic susceptibility profile similar to that of PA2 (Table 1) . Based on updated CLSI criteria (5), the ampD mutants, as well as the ampD knockout strain, manifested intermediate susceptibility to ertapenem. A high level of resistance to ertapenem has been associated with carbapenemase production or ESBL/AmpC ␤-lactamase production with porin alteration. However, based on the updated CLSI standards, several isolates of Enterobacteriaceae, especially Enterobacter cloacae, which hyperproduced AmpC ␤-lactamase without porin alteration, have been classified as resistant to ertapenem (13) . Fortunately, all of them, including isolates PA2, PA3, and PA4, remained susceptible to imipenem and meropenem, indicating that imipenem or meropenem may be preferable for infections that are caused by these organisms. Analyzing the outer membrane proteins by SDS-polyacrylamide gel electrophoresis (6) (Fig. 2) and efflux measurements (10) suggested that porin loss and efflux did not provide relevant contributions to the ␤-lactam resistance of PA2, PA3, PA4, and PA1⌬ampD.
The activity of AmpD amidase is Zn 2ϩ dependent (9). The nuclear magnetic resonance (NMR) structure suggests that Asp-164 coordinates the zinc ion in AmpD (9) . Since Asp-164 Cefazolin is highly conserved among ampD sequences of various species, it is potentially structurally and functionally important. The Asp-1643Glu substitution disrupts important catalytic or structural contacts by introducing the larger glutamic acid side chain, which inactivates AmpD (14) . A consequence of this loss-of-function mutation in ampD is the full derepression of ampC, much like that in ampD null mutations.
In conclusion, a bla ACT-9 gene that was derepressed due to the ampD mutation contributed to the in vivo development of reduced ertapenem susceptibility in a clinical isolate of P. agglomerans. This caused an inadequate response to ertapenem treatment for a bacteremic liver abscess in a patient with hepatoma. Imipenem remained active against this isolate and, in combination with abscess drainage, was successfully used in the treatment.
Nucleotide sequence accession numbers. The GenBank nucleotide sequence accession numbers for the sequences studied here were as follows: for bla ACT-9 , HQ693810; for the entire ampR-ampC region, HQ693810; for the ampD gene of isolate PA1, HQ685841; and for the ampD gene of isolates PA2, PA3, and PA4, HQ685842.
